Prosecution Insights
Last updated: April 19, 2026

CUREVAC SE

6 pending office actions

Portfolio Summary

6
Total Pending OAs
1
Final Rejections
5
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18427737 EBOLAVIRUS AND MARBURGVIRUS VACCINES PARKIN, JEFFREY S 1671 Non-Final OA Jan 30, 2024
18415477 ARTIFICIAL NUCLEIC ACID MOLECULES BERTOGLIO, VALARIE E 1632 Final Rejection Jan 17, 2024
18553531 SYRINGES CONTAINING PHARMACEUTICAL COMPOSITIONS COMPRISING RNA RYAN, DOUGLAS CHARLES 1635 Non-Final OA Sep 29, 2023
18183082 RNA ENCODING A TUMOR ANTIGEN SHIN, DANA H 1635 Non-Final OA Mar 13, 2023
18007468 NUCLEIC ACID ENCODED ANTIBODY MIXTURES HECK, BRYAN WILLIAM 1643 Non-Final OA Jan 30, 2023
18147365 RNA ENCODING AN ANTIBODY BURKHART, MICHAEL D 1638 Non-Final OA Dec 28, 2022

Managing CUREVAC SE's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month